2026
✦ Established the Smart Healthcare Division to develop products
and services centered on "sovereign AI" for the healthcare
sector.
✦ Formed a strategic alliance with APMIC (Accelerate Private
Machine Intelligence Company) to expand sovereign AI
initiatives in healthcare across Taiwan and Asia.
✦ Developed OEM services for AI-powered medical devices
and applications utilizing AI agents in healthcare.
✦ Collaborated with a medical center in Taiwan to co-develop
the first sovereign AI large language model (LLM) for
healthcare.
✦ Completed a private placement of common shares totaling
NT$30 million; paid-in capital increased to NT$216.003
million.
✦ Completed a private placement of common shares totaling
NT$20 million, alongside the exercise of employee stock
options totaling NT$1.58 million; paid-in capital reached
NT$237.583 million.
✦ Completed a private placement of common shares totaling
NT$34.2 million, alongside the exercise of employee stock
options totaling NT$5.64 million; paid-in capital reached
NT$277.423 million.
2025
✦ Completed a cash capital increase of NT$10 million, bringing
the paid-in capital to NT$161.003 million.
✦ Completed a private placement of common shares totaling
NT$25 million, bringing the paid-in capital to NT$186.003
million.
✦ Acquired a 16.22% equity stake in the UK-based company
Adtec Healthcare Limited (AHL).
✦ Initiated the certification process for medical cold plasma
devices across six Southeast Asian countries.
✦ Launched a commercialization plan for medical cold plasma
in the Taiwan market, securing entry into nine major medical
centers.
✦ Obtained a medical device code for self-pay (out-of-pocket)
use from the Kaohsiung City Public Health Bureau for medical
cold plasma devices intended for the treatment of chronic
wounds.
2024
✦ Introduced medical low-temperature plasma devices for chronic
wound treatment into major medical centers in Taiwan.
✦ Initiated the certification process for medical low-temperature
plasma chronic wound treatment devices in Southeast Asian
markets.
✦ Partnered with National Taiwan University Hospital (NTUH) to
develop innovative bioabsorbable middle-ear ventilation tubes.
✦ Began preparations for establishing an Asian manufacturing
facility for medical low-temperature plasma chronic wound
treatment devices.
✦ Completed a cash capital increase of NT$8 million, bringing
the total paid-in capital to NT$151.003 million.
2023
✦ Expansion of the market presence for medical cold-plasma
devices for chronic wound treatment into Asia.
✦ Medical cold-plasma device for chronic wound treatment
receives the first product certification of its kind in Asia
(TFDA approval).
✦ Bioresorbable magnesium-based stent project, in collaboration
with National Taiwan University Hospital (NTUH), secures a
grant under the Ministry of Science and Technology's industry
-academia cooperation program.
2022
✦ Completed a cash capital increase of NT$4.9 million, bringing
the total paid-in capital to NT$1430.03 million.
✦ Signed a memorandum of understanding (MOU) for strategic
collaboration on clinical trials for an innovative stent with NTU
Hospital Hsin-Chu Branch (National Taiwan University Hospital
Biomedical Park Branch).
✦ Began public demonstrations of the medical cold-plasma
device for chronic wound treatment in the Taiwan market.
2021
✦ Completed a cash capital increase of NT$15 million, bringing
the total paid-in capital to NT$138.103 million.
✦ Partnered with the UK-based Adtec Europe Limited (AEL) on
the first application of a medical low-temperature plasma
system for the treatment of chronic wounds.
✦ Collaborated with National Taiwan University Hospital and the
University of Tokyo on a novel stent system designed
specifically for the treatment of dialysis-related vascular
access.
2020
✦ Innovative plasma-based epidemic prevention and sterilization
equipment recognized as one of the "Top 50 Innovative
Technologies for Epidemic Prevention in Taiwan."
✦ Developed bioresorbable vascular stent technology specifically
for dialysis.
✦ Completed an "A+" advanced technology development project
focused on bioresorbable vascular stents.
✦ Initiated the development and product certification process for
advanced medical low-temperature plasma wound-healing
technology.
✦ Raised NT$9.375 million through a private placement of Class
A preferred shares, bringing the total paid-in capital to
NT$123.103 million.
2019
✦ Bioresorbable vascular stent technology has entered the animal
testing and validation phase.
✦ Surface treatment technology has been introduced for client
product validation in proton exchange membranes (PEMs) for
electric vehicle fuel cells.
✦ Bioresorbable stent technology received the "16th National
Innovation Award."
✦ Developed a "portable plasma-based anti-epidemic sterilization
and care device."
✦ Recognized by Deloitte as one of the "Technology Fast 500"
high-growth companies.
✦ Completed a cash capital increase of NT$2.75 million, bringing
the total paid-in capital to NT$113.728 million.
2018
✦ Completed the development of a patented atmospheric
-pressure plasma coating technology and initiated customer
validation for its application in the surface modification of
next-generation intraocular lens (IOL) medical devices.
2017
✦ Approved by the Taipei Exchange (TPEx) as a "publicly issued
company."
✦ Certified by the Industrial Development Bureau of the Ministry
of Economic Affairs as a "biotech and new drug company."
✦ Awarded a grant under the Ministry of Economic Affairs' "A+
Forward-looking Technology R&D Program" to develop the first
domestically produced bioresorbable vascular scaffold and its
associated technology.
✦ Completed a cash capital increase of NT$14.2 million, bringing
the total paid-in capital to NT$110.978 million.
2016
✦ Developed low-temperature, non-contact plasma modification
equipment and introduced it to a major Asian manufacturer of
intraocular lenses; collaborated on the development of new
surface modification technology for orthokeratology (corneal
reshaping) lenses.
✦ Introduced plasma modification equipment into the domestic
functional textile industry.
✦ Partnered with domestic industry, academia, and the medical
sector to develop a new generation of bioresorbable vascular
stent technology, entering the field of medical devices for
peripheral and cardiovascular interventional procedures.
✦ Completed a cash capital increase and the exercise of
employee stock options totaling NT$2.158 million, bringing
the paid-in capital to NT$96.778 million.
2015
✦ Selected as a featured vendor to showcase achievements under
the Ministry of Education's "Aim for the Top University Plan."
✦ Entered the domestic contact lens surface modification market
and expanded into the broader ophthalmic medical device
surface modification sector.
✦ Commenced sales of low-temperature, non-contact plasma
surface modification equipment for use in high-end functional
textiles.
✦ Partnered with a domestic manufacturer of neural repair
medical devices to develop bioabsorbable nerve conduit
technology.
✦ Established a medical device facility in Hsinchu, serving as a
key hub for the R&D and production of medical devices.
✦ Obtained a factory registration certificate.
✦ Secured a manufacturing-based pharmaceutical business
license.
✦ Completed a capital increase via cash issuance and the
exercise of employee stock options, totaling NT$13.82
million; post-increase paid-in capital reached NT$94.62
million.
2014
✦ Selected for the "Emerging Industry Acceleration and Incubation
Program" (Biotechnology Track) by the Small and Medium
Enterprise Administration of the Ministry of Economic Affairs
in 2014.
✦ The first enterprise in Taiwan to receive full-amount funding
from the National Development Fund's Angel Investment
Program.
✦ Completed successive cash capital increases totaling NT$42.8
million, bringing the paid-in capital to NT$80.8 million.
2013
✦ In April 2013, SG Biomedical Co., Ltd. was established with a
paid-in capital of NT$15 million.
✦ Formed a strategic partnership with N2 Biomedical, LLC (USA)
regarding surface treatment technologies for high-end medical
devices.
✦ Established operations within the National Tsing Hua University
Incubation Center.
✦ Completed subsequent cash capital increases totaling NT$22
million, bringing the total paid-in capital to NT$38 million.